• Explore /
  • Poster
  • / Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC).

Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Heinz-Josef Lenz

University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

Heinz-Josef Lenz , Eric Van Cutsem , Udit N. Verma , Marc Saltzman , Jyotsna Fuloria , Ali Khojasteh , Martin Wiesenfeld , Frank Cihon , Andrea Wagner , Axel Grothey

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01103323

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 767)

DOI

10.1200/jco.2015.33.3_suppl.767

Abstract #

767

Poster Bd #

F5

Abstract Disclosures

Similar Posters

First Author: Kaori Hayashi

First Author: Timothy Jay Price

First Author: John H. Strickler

First Author: Hirokazu Shoji